ReadingResearchRadarInvestment framework
Sign in / Sign up
← Back to reading
NewsMaterial3 min readDisconfirmAI Editorial

PwC US IPO Services Lead: Market Selective, Biotech IPOs Driven by M&A Competition

Mike Bellin, PwC's US IPO services lead, outlined the current selective standards in the US IPO market during a Crunchbase News interview: investors demand durable revenue backed by visible demand and order backlog, reasonable leverage, and for AI companies, proof of demand rather than just narrative. The biotech sector's IPO recovery is driven by competition from large pharmaceutical companies acquiring assets, creating a positive flywheel effect.

2026-11-17 20:00 GMT+8

In a recent interview with Crunchbase News, Mike Bellin, partner and U.S. IPO services leader at PricewaterhouseCoopers (PwC), offered a clear assessment of the current U.S. IPO market: it has not closed, but has become highly selective. His specific criteria are that investors are truly seeking durable revenue supported by visible demand—growth backed by strong customer bases, diversified clients, and significant order backlogs—and reasonable leverage ratios, or an equity narrative that clearly explains how debt capital generates returns.

This framework explains why the IPO market performed strongly and broadly in the first three quarters of 2026—with successful listings across industrial products, technology, consumer goods, energy, utilities, and financial services—but momentum stalled significantly after September and October. Bellin attributes this to macroeconomic uncertainty (interest rates, inflation, geopolitics) and aggressive valuations proposed in certain transactions, leading many issuers to pause and wait for the next window.

Regarding AI companies, Bellin’s distinction is more specific: investors are not skeptical of AI itself, but of spending without visibility—specifically, a lack of clear demonstration of future revenue and profitability paths. The market is dividing AI companies into two categories: those with visible demand, growth, and order backlogs, and those relying solely on narrative. He also notes that profitability can be measured in various ways, including GAAP earnings, EBITDA, free cash flow, and levered free cash flow.

Sign in / Sign up
ReadingResearchRadarInvestment framework

The most explanatory part of the interview analyzed the mechanism behind the biotech IPO resurgence. Bellin pointed out that large pharmaceutical companies, facing patent expirations, are actively seeking next-generation assets, creating a transaction landscape where both sides benefit: a single biotech company can choose an IPO for greater upside potential or an acquisition for certain immediate exit. It is precisely this M&A competition that drives the IPO market's recovery—M&A is the engine of these companies' IPO resurgence. Bellin emphasized that this flywheel effect and positive momentum have appeared in the biotech sector, whereas other market segments have not seen it in recent months.

On SPACs, Bellin believes market volatility is driving renewed interest because SPACs set valuation certainty on day one, allowing companies seeking exits to understand the potential cash size they might receive. However, he noted that there is still a large inventory of SPACs looking for targets; while the market is healthier and more mature than in the past, inventory pressure remains.

It must be emphasized that Bellin’s framework represents the observations and judgments of an IPO services practitioner, not independently verified market data. His criteria describe what he observes investors demanding, rather than a guaranteed formula for success. Market selectivity can change rapidly with macroeconomic conditions; he expects the strength of early 2027 to depend on whether momentum can be rebuilt in the remaining months of 2026.

Sources

  • news.crunchbase.comCrunchbase News↗
Continue researching →